A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3532226 in Healthy Participants
Latest Information Update: 22 Dec 2021
At a glance
- Drugs LY 3532226 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 16 Dec 2021 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2021 Status changed from not yet recruiting to recruiting.